Reduction of Relapses in Multiple Sclerosis after Anti-Alpha4 Integrin Antibody (Natalizumab)
| Autor: | William A. Sheremata, M. Koller, Timothy Vollmer, Alireza Minagar, A. J. Willmer-Hulme |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Advanced and Specialized Nursing
medicine.medical_specialty biology Cell adhesion molecule business.industry medicine.drug_class Multiple sclerosis Integrin medicine.disease Monoclonal antibody Placebo Gastroenterology Natalizumab Pharmacokinetics Internal medicine Immunology medicine biology.protein Neurology (clinical) Antibody business medicine.drug |
| Zdroj: | International Journal of MS Care. 2:2-5 |
| ISSN: | 1537-2073 |
| Popis: | Anti-alpha4 integrin antibody, natalizumab (Antegren), is a monoclonal antibody to a4b1 integrin adhesion molecules expressed on activated monocytes and CD4 cells. A 1-year followup of 28 patients with relapsing multiple sclerosis, randomized to 3 groups in a double-blind pharmacokinetic study, are presented. One group received placebo, a second group low doses (0.01–0.3 mg/kg) of natalizumab, and a third group high doses (1–3 mg/kg) of natalizumab. The observed reduction of relapses in all natalizumab-treated patients with multiple sclerosis suggests a potential range of doses to induce stabilization of the disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|